Inclusion Criteria:

          1. Male or female, 18 to 70 years old (including 18 and 70 years old)

          2. BCMA antigen diagnosed by pathology and histological examination was positive

          3. ECOG ≤2，and the excepted survival ≥ 3 months

          4. Patients with BCMA+ myeloma who received ≥ 1 line of chemoradiotherapy or tumor
             relapsed

          5. The main organs function is good; （1） liver function: ALT/AST<3 times normal value
             upper limit (ULN) and total bilirubin <34.2 (mol/L); （2） renal function: creatinine
             <220 mu /L,GFR > 30mL/min; （3） lung function: blood oxygen saturation is greater than
             95%; （4） cardiac function: left ventricular ejection fraction (LVEF) is greater than
             50%;

          6. Platelets > 40 billion/L;

          7. Patients without any anti-cancer treatment such as chemotherapy，radiotherapy,
             immunotherapy（ immunosuppressive drugs ）within 2-4 weeks before, and the
             treatment-related toxicity reaction ≤1 level prior to enrollment（except low toxicity
             lose hair for example）

          8. Venous channel is unobstructed, which can meet the needs of intravenous drip;

          9. Voluntary informed consent is given, agree to follow the trial treatment and visit
             plan.

        Exclusion Criteria:

          1. Patients with allergy to large molecules such as antibodies or cytokines;

          2. More than 5mg of hormones (except patients with inhaled hormone) were used within 2 to
             4 weeks prior enrollment;

          3. Patients with severe autoimmune diseases or immunodeficiency diseases;

          4. Patients treated with other immune cellular products (DC, CIK, T, NK, and CART
             products with CD19 or other targets);

          5. Patients with uncontrollable infectious disease in the first 4 weeks of treatment;

          6. Active hepatitis B DNA > 1000copy/mL/ , hepatitis C positive, (HCV positive
             resistance, HCV RNA positive);

          7. Patients participated in other clinical trials within 6 weeks prior enrollment;

          8. Patients with mental illness;

          9. Patients with drug abuse/addiction and medical, psychological or social conditions may
             interfere with the study or evaluate the results of the study;

         10. Patients have alcohol dependence;

         11. Pregnant or lactating women; Men or women who have a pregnancy plan within a year; The
             patients cannot guarantee effective contraceptive measures during the trial period;

         12. Patients had other conditions that were not appropriate for the group determined by
             the researchers.